The U.S. Food and Drug Administration (FDA) is conducting market research to identify small business sources capable of providing a service agreement for the maintenance and repair of a 3730xL genetic analyzer instrument. The procurement aims to ensure uninterrupted operation of this critical equipment, which is essential for DNA sequencing and related research activities conducted by the Center for Biologics Evaluation and Research (CBER). The service agreement will include scheduled preventive maintenance, unlimited corrective maintenance, software updates, and technical support, with the contract period starting from July 1, 2025, through June 30, 2026, with options for two additional years. Interested parties must submit their capability statements by May 14, 2025, to Nick Sartain at nick.sartain@fda.hhs.gov.